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Abstract
Background: A novel injectable cement composed of chitosan-bonded borate bioactive glass (BG) particles was evaluated
as a carrier for local delivery of vancomycin in the treatment of osteomyelitis in a rabbit tibial model.
Materials and Methods: The setting time, injectability, and compressive strength of the borate BG cement, and the release
profile of vancomycin from the cement were measured in vitro. The capacity of the vancomycin-loaded BG cement to
eradicate methicillin-resistant Staphylococcus aureus (MRSA)-induced osteomyelitis in rabbit tibiae in vivo was evaluated and
compared with that for a vancomycin-loaded calcium sulfate (CS) cement and for intravenous injection of vancomycin.
Results: The BG cement had an injectability of .90% during the first 3 minutes after mixing, hardened within 30 minutes
and, after hardening, had a compressive strength of 1862 MPa. Vancomycin was released from the BG cement into
phosphate-buffered saline for up to 36 days, and the cumulative amount of vancomycin released was 86% of the amount
initially loaded into the cement. In comparison, vancomycin was released from the CS cement for up 28 days and the
cumulative amount released was 89%. Two months post-surgery, radiography and microbiological tests showed that the BG
and CS cements had a better ability to eradicate osteomyelitis when compared to intravenous injection of vancomycin, but
there was no significant difference between the BG and CS cements in eradicating the infection. Histological examination
showed that the BG cement was biocompatible and had a good capacity for regenerating bone in the tibial defects.
Conclusions: These results indicate that borate BG cement is a promising material both as an injectable carrier for
vancomycin in the eradication of osteomyelitis and as an osteoconductive matrix to regenerate bone after the infection is
cured.
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Local delivery of high doses of antibiotics is desirable in treating
osteomyelitis because it can facilitate the delivery of antibiotics by
diffusion to avascular areas that are inaccessible by systemic
antibiotics while minimizing potential systemic toxicity [3]. In
some cases, infecting organisms that are resistant to drug
concentrations achieved by systemic antibiotics are susceptible to
the higher drug concentrations provided by local antibiotic
delivery. Poly(methyl methacrylate) (PMMA), calcium sulfate
(CaSO4), calcium phosphate ceramics such as hydroxyapatite
(HA) and beta-tricalcium phosphate (b-TCP), and biodegradable
polymers, synthetic or natural, such as poly(lactic acid) poly
(glycolic acid), and their copolymers, collagen and chitosan) have
been widely studied or used as carriers for local drug delivery
[4,5]. However, those carriers have limitations such as bioinertness

Introduction
Curing osteomyelitis (bone infection) presents a clinical challenge because once infection has entered bone, it is difficult to
treat. Furthermore, the infection has a significant relapse rate
despite gradual advances in surgical techniques and the development of novel antimicrobial agents over many years [1,2].
Osteomyelitis can occur at all ages and diabetic patients are
particularly susceptible to the infection. Osteomyelitis is also
becoming more common in orthopedic surgery as the number of
hip and knee joint replacements increases with an aging
population. The treatment for osteomyelitis includes removing
the infected areas of bone followed by months of extensive
intravenous antibiotic treatment.
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(e.g., PMMA) or inadequate degradation rate (e.g., HA), poor
osteoconductivity, rapid antibiotic elution rate, transient cytotoxicity, and low strength [6,7].
In recent years, various compositions of borate glass have been
investigated for biomedical applications because they are bioactive, biocompatible and osteoconductive. Borate-based bioactive
glasses (BG) degrade and convert more rapidly and more
completely to HA than the more widely studied silicate bioactive
glasses such as 45S5 glass when placed in an aqueous phosphate
solution such as body fluid [8210]. Furthermore, the degradation
rate of borate-based BG can be controlled by changing the B2O3
content of the glass to SiO2 to form borosilicate bioactive glasses
[11]. Our previous studies have demonstrated that borate BG
pellets can serve as a carrier for sustained delivery of antibiotics in
vitro and in vivo, and for the treatment of osteomyelitis in a rabbit
model [12214].
Injectable biomaterials can be implanted using minimally
invasive surgical techniques, resulting in less pain, shorter recovery
time, and lower healthcare cost when compared to conventional
surgery. They are also more convenient for filling irregular-shaped
bone defects, leaving little dead space for bacterial survival.
Injectable calcium sulfate (CS) loaded with antibiotics is one of the
most widely studied materials [15217], but it suffers from
limitations such as rapid resorption and antibiotic release rates,
low mechanical strength, rapid reduction in its mechanical
strength with time in vivo, and transient cytotoxic effects leading
to inflammatory reactions [18,19].
In this study, we constructed an injectable local antibiotic
delivery system, which was composed of both powder and liquid
components. The powder component was borate glass. The liquid
component was a solution of chitosan, citric acid and glucose. As
described earlier, borate BG has several properties which make it
attractive for biomedical applications. Chitosan, which has high
viscosity in solution and excellent biocompatibility, is a useful
carrier for controlled release of drugs because of its complexation
property [20]; it can also be used as a binder to improve the
elution characteristics of antibiotic carrier materials [21]. Citric
acid has three carboxyl groups and one hydroxyl group, which can
be cross-linked with chitosan to increase the viscosity of the liquid
phase. Citric acid could also undergo a chelation reaction with
calcium in borate BG, and thereby influence setting times,
mechanical properties and biocompatibility of cements. Glucose
which contains five hydroxyl groups could react with citric acid,
and inhibit its effect. The optimal weight ratio of chitosan, citric
acid and glucose was justified in our preliminary research, which
we used to design cement with an appropriate setting time and
mechanical properties.
The objective of this study was to evaluate borate BG cement as
a carrier of vancomycin in the treatment of osteomyelitis in a
rabbit tibial model. Vancomycin was used because it is a broadspectrum glycopeptide antibiotic that is active against Grampositive bacteria. It is used clinically to treat osteomyelitis in
patients who are allergic to penicillin or who are infected with the
bacterium methicillin-resistant Stayphylococcus aureus (MRSA) [22].
The key physico-chemical characteristics of the BG cement and
the release profile of vancomycin from the cement were measured
in vitro, while the capacity of the BG cement to eradicate
osteomyelitis in rabbit tibiae at 2 months post-surgery was
evaluated using radiography, microbiological testing, and histology. For comparison, the capacity of a vancomycin-loaded
commercial CS cement to eradicate the osteomyelitis was also
studied.

PLOS ONE | www.plosone.org

Materials and Methods
Ethics statement
The study protocol adhered to the recommendations of the US
Department of Health for the care and use of laboratory animals
and was approved by the Ethics Committee of Shanghai Jiao
Tong University.

Preparation of vancomycin-loaded borate BG cement
The injectable cement used in the present study was composed
of borate BG particles bonded together with chitosan. BG with the
composition (mol%) 6Na2O–8K2O–8MgO–22CaO–54B2O3–
2P2O5 was prepared by conventional methods and ground to
form particles of ,10 mm in size, as described previously [11]. The
bonding phase was prepared by mixing chitosan, citric acid and
glucose in the ratio 1:10:20 (by weight) to form a solution. To
prepare the BG cement, a mixture of vancomycin powder (Eli
Lilly; Japan) and BG particles (80 mg of vancomycin per gram of
BG) was added to the bonding solution (weight ratio of solid phase
to liquid = 2:1), and the system was mixed for 1 minute in a
mortar and pestle to form a paste. For comparison, an injectable
putty was prepared by mixing vancomycin powder, a commercially available CS powder (AllomatrixH; Wright Medical) and the
mixing solution provided with the CS powder, as recommended
by the manufacturer. The same concentration of vancomycin was
used in both the BG paste and the CS putty, equal to 8 wt% of the
BG or CS. Prior to use, the solid starting materials were sterilized
by ã-irradiation (25 kGy), and all materials were prepared under
sterile conditions.

Characteristics detection
The initial and final setting times of the vancomycin-loaded
borate BG paste (formed as described above) were measured at
room temperature using a standard test by means of Gillmore
needles, as described in ASTM C266–99 [23]. The injectability of
the paste was evaluated using an extrusion test, as described
previously [24]. Briefly, after mixing, the paste was loaded into a
commercial syringe with a capacity of 20 mL and an opening
2 mm in diameter. At selected times from the completion of the
mixing step, the paste was extruded from the syringe (held rigidly
in a fixture) by applying a force using a universal testing machine
(BIONIX; MTS, Eden Prairie, MN) at a crosshead speed of
15 mm/min. The extrusion was stopped when the applied force
reached 100 N. The injectability coefficient (I) was defined as
I ~ ½ðMo {M Þ=Mo |100

ð1Þ

where Mo is the initial mass of the cement loaded into the syringe,
and M is the mass remaining in the syringe after extrusion. At each
time point, 6 samples of the cement were tested, and the results are
expressed as a mean 6 standard deviation (SD).
The compressive strength of the borate BG cement was
measured as a function of immersion time in phosphate buffered
saline (PBS) at 37uC using a mechanical testing machine
(BIONIX, MTS, MN) at a crosshead speed of 0.5 mm/min.
Cylindrical samples (6 mm in diameter 615 mm) of the asfabricated cement (formed by allowing the BG paste to harden for
30 minutes), and the as-fabricated cement immersed in PBS for
various times (12, 24, 48, 96 and 168 h) were tested. Six samples
were tested at each time point and the results are expressed as
mean 6 SD. The surface morphology and structure of the BG
cement, before and after immersion in PBS, were examined using
a field-emission scanning electron microscope (SEM) with an
energy dispersive X-ray spectroscopy (EDS) analysis unit attached
2
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(Quanta 200 FEG, FEI Co., The Netherlands). There is a table
arrived from the EDS analysis, which showed the contents of all
element presented in the sample. The Ca/P ratio was calculated
from these contents of Ca and P. X-ray diffraction (XRD; Model
D/max 2550 v, Rigaku International Corp., USA) (Cu Ka
radiation;l15406 nm) at a scan rate of 1.0u2h per minute was
also performed.

tissues were used to confirm MRSA infection. After debridement,
the cements were injected into the medullary space of the defects
to treat the infection. Then the surgical wounds were sutured and
disinfected. The animals were closely monitored after surgery and
normal activity was allowed.

Blood analysis
Before surgery and at monthly intervals post-surgery, venous
blood was taken from the animals and used to measure the white
blood cell count (WBC), and to analyze liver and renal function,
including glutamate-pyruvate transaminase (GPT), glutamicoxal(o)acetic transaminase (GOT), urea (Ur) and creatinine (Cr).
The concentration of vancomycin in the serum of animals in
Groups 3 and 4 was measured as a function of implantation time
using HPLC, while the boron concentration in the serum of the
Group 4 animals was measured from 1 h to 7 days post-surgery
using inductively coupled plasma-atomic emission spectroscopy
(ICP-AES; Optima 2100DV, USA).

Antibiotic release study
The release of vancomycin from the BG and CS cements was
measured using cylindrical samples (6 mm in diameter 615 mm)
immersed in sterile PBS at 37uC. Each sample was immersed in
10 mL PBS, and the medium was collected and replaced with
fresh PBS every 48 h until no vancomycin could be detected in the
medium (detection limit ,0.2 mg/mL). The concentration of
vancomycin in the medium was measured using high-performance
liquid chromatography (HPLC) as described previously [25]. The
percentage of vancomycin released into the medium was
determined from the measured amount of vancomycin in the
medium and the amount initially loaded into the cements. In order
to determine whether the antibacterial activity of vancomycin was
affected by the cement preparation process, the antibacterial
activity of the vancomycin eluted from the cements was compared
with that for the as-received vancomycin. Testing for the
minimum inhibitory concentration (MIC) of vancomycin against
MRSA (ATCC43300) was performed using an antibiotic 2-fold
tube dilution method described elsewhere [26], which yielded
0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 mg/mL drug concentrations
in 10 tubes with 2 mL sterile cation-supplemented Mueller-Hinton
broth (Oxoid). The tubes were then inoculated with MRSA at 107
CFU/mL. Three no-drug tubes (not inoculated with any
bacterium, inoculated with MRSA, and inoculated with standard
bacterium) were also performed as control. MIC was the lowest
concentration of antibiotic that prevented turbidity after 24 h of
incubation at 37uC.

Radiographic evaluation
Standard digital anterior2posterior and lateral radiographs of
the right hind limbs were taken before surgery and at 2 months
post-surgery. Periosteal new bone formation (PNBF), sequestral
bone formation (SBF) and destruction of bone (DB) were used to
evaluate the severity of osteomyelitis by two radiologists in a
blinded independent manner. The radiographs were also evaluated using the scoring system described by Norden et al. [27].
Briefly, four radiographic parameters (presence of SBF, presence
of PNBF, presence of DB and extent of involvement) were
evaluated for each radiograph. A numerical score was assigned to
each variable. All four scores were added together to give an
overall ranking for radiographic severity. A higher score represented increased severity of osteomyelitis.

Microbiological evaluation
The animals were euthanized by intravenous administration of
pentobarbital sodium at 2 months post-surgery. Using sterile
techniques, swab specimens for microbiological examination were
immediately taken from the bone, the marrow and the surrounding area of soft tissues. They were inoculated on blood agar and
incubated for 48 h at 37uC. Identification of S. aureus was
performed with the coagulate tube test and the API Staph system
(ATB 32Staph. Bio-Merieux, Marcy-l9Etoile, France). Resistance
to methicillin was further confirmed by detection of the mecA gene
using PCR.

Surgical procedure
Seventy adult New Zealand White rabbits (mean weight =
2.20 kg; range = 1.8–2.7 kg) were used in this study. Osteomyelitis
was induced in the right tibia of the rabbits using the method
described by Norden et al. [27]. Briefly, under general anesthesia
with 3% sodium pentobarbital (1 mL/kg), the proximal part of the
tibia was exposed and a hole was created manually through the
cortex into the medullary cavity using a needle. Then 0.1 mL of
5% sodium morrhuate, 0.1 mL of MRSA suspension
(16108 CFU/mL) and 0.1 mL of sterile PBS were injected
sequentially into the medullary cavity. Four weeks later, the
presence of osteomyelitis was evaluated from radiographs by two
radiologists, independently and in a blinded manner, according to
the scoring system described by Norden et al.
Sixty-three animals that developed osteomyelitis were chosen
for subsequent studies. Five animals were sacrificed for microbiological and histological examination. The remaining animals
were randomly divided into 4 groups. The animals in Group 1
(n = 10) did not receive any further treatment, while the Group 2
animals (n = 16) were treated by debridement and daily intravenous injection of vancomycin (6 mg per kg body weight) for
one month; the animals in Group 3 (n = 16) were treated by
debridement followed by implantation of injectable vancomycinloaded CS cement, and the animals in Group 4 (n = 16) were
treated by debridement followed by implantation of injectable
vancomycin-loaded BG cement. Debridement was performed by
making a cortical bone window (2.022.561.0 cm), and removing
the purulent marrow by saline lavage. Samples of the debrided
PLOS ONE | www.plosone.org

Histopathological evaluation and SEM analysis
After the rabbits were sacrificed, samples of the defects together
with surrounding bone were taken and fixed in 10% formalin for
7 days, then decalcified in EDTA and embedded in paraffin using
routine histological techniques. The embedded specimens were
serially sectioned (5 mm thickness) in the original longitudinal
direction and the sections were stained with hematoxylin and eosin
(H&E) for histological examination. All sections were examined
and evaluated for intraosseous acute inflammation (IAI), intraosseous chronic inflammation (ICI), periosteal inflammation (PI) and
bone necrosis (BN) using the scoring system described by Smeltzer
et al. [28]. Samples from the Group 4 animals (implanted with the
BG cement) were also examined by SEM (Quanta 200 FEG). The
tissue in the defect area was cut in the original transverse direction
to give sections of 3–5 mm thickness. The specimens were fixed
using 5% glutaraldehyde phosphate solution, dehydrated through
a graded series of ethanol, and examined by SEM.
3
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Statistical analysis
All data were analyzed using the Statistical Package for the
Social Sciences, Version 13.0 (SigmaStat, SPSS Science, Chicago,
IL, USA), and the results were expressed as mean 6 standard
deviation (SD). A one-way ANOVA was performed to assess
significant differences among WBC counts, liver and renal
function, radiographic scores and histopathological scores of the
four groups. MRSA infection rates of the four groups identified by
Radiographic evaluation and Microbiological evaluation were
analyzed qualitatively by chi-square test. Differences were
considered to be significant at P,0.05.

Results
Characteristics of vancomycin-loaded borate BG cement
in vitro

Figure 2. Compressive strength of vancomycin-loaded borate
BG cement after hardening and as a function of immersion
time in phosphate-buffered saline (PBS) in vitro.
doi:10.1371/journal.pone.0085472.g002

The initial and final setting times of the vancomycin-loaded
borate BG cement were 8.162.3 min, and 27.666.4 min,
respectively. The percent injectability of the cement (Fig. 1)
remained above 90% during the first 3 minutes after the mixing
step, and decreased rapidly thereafter. As prepared, the vancomycin-loaded cement had a compressive strength of 18.262.3
MPa; upon immersion of the cement in PBS, the strength
decreased to 15.061.8 MPa after 1 day and more gradually
thereafter, to 12.261.8 MPa after 7 days (Fig. 2). SEM of the
surface of the hardened vancomycin-loaded BG cement showed a
heterogeneous microstructure with some pores, which might be
caused by bubbles produced during the mixing process (Fig. 3a).
After immersion in PBS for 10 days, a few particles, composed of
Ca and P according to EDS analysis (Fig 3d), formed on the
surface of the specimens (Fig. 3b). After immersion for 40 days, the
precipitated particles almost covered the whole surface of the
cement which appeared denser and more uniform (Fig. 3c); EDS
analysis showed that the Ca/P atomic ratio of the particles was
1.6060.22, which is close to the value for stoichiometric
hydroxyapatite (1.67). The XRD pattern of the samples also
showed characteristic peaks similar to reference hydroxyapatite
(JCPDS 72–1243) (Fig 3e).

the BG cement at 2 days was 44% of the total amount initially
loaded into the as-prepared cement, compared to 48% for the CS
cement. At day 36, the cumulative amount of vancomycin
released from the BG cement was 86%, after which no measurable
release was observed (detection limit ,0.2 mg/mL). In comparison, the cumulative amount of vancomycin released from the CS
cement was 89% at day 28, after which no further release was
detected. The MICs of all three groups (non-processed vancomycin, vancomycin released from borate BG cement and CS cement)
were 1 mg/mL, indicating that the cement preparation process did
not affect the antibacterial activity of the vancomycin (Fig. 5).

Blood analysis of animals implanted with vancomycinloaded borate BG cement
Although there were fluctuations, the white blood cell (WBC)
counts and the liver and renal functions at sacrifice showed no
measurable differences from preoperative values. The boron
concentration in the serum of the animals implanted with
vancomycin-loaded BG cement reached a peak at 36 h postsurgery, and gradually decreased thereafter (Fig. 6a). The
vancomycin concentration in the serum of the animals implanted
with BG cement or CS cement remained at a low level (Fig. 6b). In
the Group 4 animals, the vancomycin concentration reached a
peak (4.4 mg/mL) at 24 h post-surgery and decreased to a value
below the detection limit (0.2 mg/mL) at day 12. In comparison,
the concentration reached a peak value of 5.1 mg/mL in the
Group 3 animals at 20 h post-surgery and decreased to a value
below the detection limit at day 8.

Vancomycin release profile and antibacterial activity in
vitro
The release profiles of vancomycin from the BG cement and the
CS cement into PBS (Fig. 4) showed a more rapid release during
the first 2 days, followed by a slower, more sustained release
thereafter. The cumulative amount of vancomycin released from

Radiographic evaluation
For all the animals used in this study, typical signs of bone
infection including SBF, DB, and PNBF were seen in the
radiographic images before surgery, and no clear differences were
observed among the groups. Two months post-surgery, radiographic images of the tibiae showed significant improvement in the
Group 3 and 4 animals (Fig. 7). Only 2 of the 16 animals in each of
those two groups showed the presence of osteomyelitis, indicating
the capacity of both treatments to cure the bone infection. In
comparison, 9 of the 16 animals in Group 2 and all 10 animals in
Group 1 still showed signs of osteomyelitis. The numbers of
infected animals in Groups 3 and 4 were significantly lower than
those in Groups 1 and 2 (Table 1). The mean radiographic scores
of the Group 3 and Group 4 animals were also significantly lower
than those of Groups 1 and 2 (Fig. 8).

Figure 1. Percent injectability of vancomycin-loaded borate
bioactive glass (BG) cement as a function of time after mixing.
doi:10.1371/journal.pone.0085472.g001

PLOS ONE | www.plosone.org
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Figure 3. Characteristics of vancomycin-loaded borate BG cement in vitro. SEM images of the surface of vancomycin-loaded borate BG
cement as fabricated (after hardening) (a) and after immersion in PBS for 10 days (b) and for 40 days (c). EDS analysis showed that particles formed on
the surface of the specimens were composed of Ca and P (d). After immersion in PBS for 40 days, the XRD pattern of the samples showed similar
peaks to those characteristic of reference hydroxyapatite (JCPDS 72–1243) (e).
doi:10.1371/journal.pone.0085472.g003

Microbiological evaluation
The eradication of osteomyelitis was also evaluated by
microbiological testing (Table 1). Two months post-surgery, all
10 animals in Group 1 and 9, 3, and 2 animals, respectively, of
the 16 animals in each of Groups 2, 3, and 4 tested positive for
MRSA-induced infection by cultivation in BHI bouillon at 37uC
for 7 days. The number of animals that tested positive in Groups

Figure 5. The MIC against MRSA for vancomycin was determined using the antibiotic twofold tube-dilution method. Three
no-drug tubes (not inoculated with any bacterium, inoculated with
MRSA, and inoculated with standard bacterium) were also performed as
control. MIC was the lowest concentration of antibiotic that prevented
turbidity after 24 h of incubation at 37uC. In this study, the MICs of all
three groups (non-processed vancomycin, vancomycin released from
borate BG cement and CS cement) were 1 mg/mL.
doi:10.1371/journal.pone.0085472.g005

Figure 4. Vancomycin release profile in vitro. (a) Concentration of
vancomycin released from borate BG cement and calcium sulfate (CS)
cement into PBS at different time points; (b) cumulative amount of
vancomycin released (as a percentage of the amount initially loaded
into the cements) as a function of immersion time in PBS.
doi:10.1371/journal.pone.0085472.g004

PLOS ONE | www.plosone.org
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Figure 7. Radiographics analysis of animals before surgery and
at 2 months post-surgery. Representative preoperative radiographs
showing tibial osteomyelitis in the four different groups (1a, 2a, 3a, 4a),
characterized by bone destruction (arrows), periosteal new bone
formation (arrowhead) and sequestral bone formation (asterisk). (1b)
Postoperative radiographs of Group 1 showed deterioration of
osteomyelitis coupled with periosteal new bone formation (arrowhead),
destruction of bone (arrows) and sequestral bone formation (asterisk).
(2b) Postoperative radiographs of Group 2 showed that the osteomyelitis was partly controlled. (3b, 4b) Postoperative radiographs of Group
3 and Group 4 showed that the osteomyelitis was healed.
doi:10.1371/journal.pone.0085472.g007

Figure 6. Blood analysis of animals implanted with cements. (a)
Boron concentration in the serum of rabbits implanted with vancomycin-loaded borate BG cement as a function of time post-surgery; (b)
vancomycin concentration in the serum of rabbits implanted with
borate BG cement and CS cement as a function of time post-surgery.
doi:10.1371/journal.pone.0085472.g006

3 and 4 was significantly lower than the pre-operative number
and the numbers in Groups 1 and 2. However, the difference
between the number in Group 3 and in Group 4 was not
significant.

Discussion
Histological Examination and SEM analysis

In general, carriers for local antibiotic delivery in the treatment
of osteomyelitis should provide the requisite antibiotic delivery
rate, be osteoconductive to enhance bone regeneration after the
infection is cured, and have the requisite mechanical strength to

Histological evaluation using light microscopy showed clear
differences in the appearance of the bone defect area among the
four groups of animals (Fig. 9). In Group 1, the defect area was
replaced by connective tissue and there were many inflammatory
cells in the area; sequestered bone formation and destruction of
bone could also be observed (Fig. 9a). In Group 2, no typical signs
of osteomyelitis were observed in some defects; some inflammatory
cells infiltrated the defect area and there was little new bone
formation (Fig. 9b). The implants in Group 3 were almost
completely degraded and there was modest new bone formation
(Fig. 9c); the presence of some macrophages near the degraded
materials indicated the phagocytic process of the host to dissolve
the CS cement. Some connective tissue was also found around the
newly formed bone. In Group 4, a considerable amount of new
bone was formed along with the degradation and conversion of the
BG glass in the cement, and the new bone was intimately attached
to the surface of the implant or had infiltrated the implant (Fig. 9d).
The histological score for Group 4 (2.060.8) at 2 months postsurgery was significantly lower than the pre-operative score, and it
was the lowest value among the four groups (Fig. 8). SEM images
of the defects implanted with the vancomycin-loaded BG cement
showed many micro-cavities and pores in the implants, with some
cells and fibers growing into them. (Fig. 10a–c).

PLOS ONE | www.plosone.org

Figure 8. Radiographic scores and histological scores for rabbit
tibiae infected with osteomyelitis prior to treatment (preoperative) and after 8 weeks of treatment in the 4 groups.
Group 1: no treatment; Group 2: intravenous injection of vancomycin;
Group 3: vancomycin- loaded CS cement; Group 4: vancomycin-loaded
borate BG cement. (mean 6 SD; *, ** significantly different to the
corresponding scores for the other groups, P,0.05).
doi:10.1371/journal.pone.0085472.g008
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Table 1. Comparison of the capacity of the 4 treatment mentods to eradicate MRSA-induced osteomyelitis in rabbit tibiae at
8 weeks post-surgery.

Total number

Number eradicated
(radiology)

Number eradicated
(microbiology)

Group

Treatment

1

No treatment

10

0

0

2

Intravenous vancomycin

16

7

7

3

Vancomycin-loaded CS cement

16

14

13

4

Vancomycin-loaded BG cement

16

14

14

doi:10.1371/journal.pone.0085472.t001

The borate BG cement self-hardened when the separate
components were mixed together. The setting reactions of the
injectable borate BG cement could be divided into two stages. The
initial reaction was a chelation reaction between citric acid and
calcium in the borate BG, which happened when the powder
component and the liquid component were mixed in vitro. The
second reaction involved transformation of the cement components to HA, which occurred when the cements were placed in an
aqueous phosphate solution, such as PBS or body fluid. The
setting time of the initial reaction could be modulated by changing
the concentration of citric acid and glucose [30,31]. The initial
and final setting times of borate BG cement were 8 and 28 min,
respectively, which were longer than those of calcium phosphate
cements [32]. This extended setting time could offer the surgeons
more time for operation, and it allowed the cements to fill the
irregular bone cavity.

support physiological loads [3,29]. In this study, we evaluated a
borate BG cement, composed of borate glass particles, chitosan,
citric acid and glucose, as an injectable local antibiotic delivery
system. When compared to a commercial calcium sulfate (CS)
cement used clinically, the borate BG cement showed a more
sustained release of vancomycin in vitro and a similar capacity to
eradicate MRSA-induced osteomyelitis in a rabbit tibial model in
vivo. Whereas the CS cement degraded and induced a local
inflammatory reaction in the tibial defects, the borate glass
particles in the BG cement converted to HA and supported
considerable bone regeneration in the defects within the twomonth implantation period. Based on these characteristics, the
vancomycin- loaded borate BG cement used in the present study
has potential for curing osteomyelitis and for regenerating bone
after the infection is cured.

Figure 9. Representative images of H&E stained sections of rabbit tibiae at 2 months post-surgery. (a) Group 1 (no treatment): Typical
signs of osteomyelitis, including destruction of bone (DB), intramedullary abscess (IA), with virtually no new bone formation; (b) Group 2 (intravenous
injection of vancomycin): no typical signs of osteomyelitis and little new bone formation; (c) Group 3 (vancomycin-loaded CS cement): the CS cement
was mostly degraded with only limited new bone formation (white arrow) surrounding it, and some macrophages near the degraded material (CS);
(d) Group 4 (vancomycin-loaded borate BG cement): a considerable amount of new bone (white arrow) was formed which was in direct contact with
the degraded implant (BG). (Bar = 200 mm).
doi:10.1371/journal.pone.0085472.g009
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Figure 10. SEM images of the cement after implantation for 8 weeks in rabbit tibiae infected with MRSA-induced osteomyelitis. The
BG implant became porous (a), was bonded to osteoid tissues (OT) at the interface (arrow) (b), and some cells (C) and fibrous tissue (F) adhered to the
implant (c).
doi:10.1371/journal.pone.0085472.g010

In addition, the borate BG cement had an injectability of .90%
within the first 3 min after mixing, which was also favorable for
clinical use. The strength of the BG cement is appropriate for
supporting physiological loads, with a compressive strength, after
hardening, of 18.262.3 MPa, which is lower than that of other
bioactive glass-ceramics [30]. A reduction in strength occurred
after immersion of the cement into PBS. However, after
immersion in PBS for 7 days, the strength of the cement was
still comparable to the highest strength reported for trabecular
bone (2212 MPa). Therefore, the compressive strength of borate
BG cement is favorable for application in the repair of
osteomyelitis-induced contained bone defects, where adjacent
cortical bone could provide mechanical rigidity and support to
withstand shear and tensile stress [33].
When placed in an aqueous phosphate solution, borate BGs
degrade and convert to an amorphous calcium phosphate (ACP)
that subsequently crystallizes to HA. As the glass degrades,
calcium ions released from the glass react with phosphate ions
from the medium to precipitate ACP (or HA) on the surface of the
glass. In vivo, the presence of carbonate ions in the body fluid leads
to the formation of a carbonate-substituted HA in which a fraction
of the phosphate ions are substituted by carbonate ions. The
formation of this carbonate-substituted HA leads to a bioactive
and osteoconductive material that bonds strongly to bone.
Incorporation of collagen and other proteins into the carbonatesubstituted HA during the conversion process results in a material
with bone-like features. In the present study, immersion of the
vancomycin-loaded borate BG cement in PBS in vitro apparently
resulted in the precipitation of HA on the surface of the cement,
because the chitosan bonding phase does not degrade in the
absence of biological proteins. However, within 2 months of
implantation in rabbit tibial defects, the cement formed an implant
that had a good biocompatibility with the host bone and showed
the presence of adherent cells and fibers.
The release of vancomycin from both borate BG cement and
CS cement into PBS in vitro showed the same general profile: a
more rapid release initially (first 2 days) followed by a more
sustained release thereafter. However, the borate BG cement
showed a slower and more sustained release. The release of
vancomycin from the borate BG cement also lasted for a longer
period when compared to vancomycin-loaded borate glass
particles and antibiotic-loaded glass/PMMA composite [12,34].
In the present study, the free amine groups in the polymeric chains
of chitosan were able to interact with negatively-charged groups in
the polymers and with polyanions [35]. Consequently, crosslinking could occur between the amine groups of chitosan and
phosphate (PO4)32 ions in the PBS which could reduce the release
rate of vancomycin. The antibiotic activity of vancomycin released
PLOS ONE | www.plosone.org

from borate BG cement in vitro was similar to that of the asreceived vancomycin, which indicates the feasibility of the cement
preparation process for clinical application. The vancomycin
concentrations in the eluents exceeded the MIC for MRSA but
was lower than the toxic concentration, so could ensure local
effective bactericidal concentration with no inhibition of bone
regeneration [36,37].
The boron and vancomycin concentrations in the serum of the
infected rabbits implanted with vancomycin-loaded borate BG
cement were well below the toxic levels throughout the
implantation period. Concerns about the toxicity of boron and
vancomycin released from the borate BG cement can therefore be
allayed. Radiography and microbiological tests showed that when
loaded with vancomycin, both the borate BG cement and the CS
cement were significantly more effective than intravenous injection
of vancomycin in eradicating MRSA-induced osteomyelitis in the
rabbit tibiae. While the borate BG cement showed a more
sustained release of vancomycin in vitro, there was no significant
difference in the capacity of the two implant materials to eradicate
osteomyelitis.
The ability to promote bone formation after curing infection is
desirable because osteomyelitis is often associated with bone loss
[38]. A considerable amount of new bone was formed in the
defect sites implanted with borate BG cement at the end of the
two-month implantation. No inflammatory cells were observed in
the vicinity of the vancomycin-loaded BG cement, indicating the
biocompatibility of that cement in vivo. In comparison, the CS
cement degraded rapidly and caused local inflammation, a
finding in agreement with the reported drawbacks of calcium
sulfate in vivo [39,40].

Conclusions
A vancomycin-loaded biomaterial composed of borate BG
particles bonded with chitosan had initial and final setting times of
,8 and ,28 min, respectively, rendering the material suitable for
use as an injectable cement. With a compressive strength of
18.262.3 MPa after hardening, the cement could be used in some
load-bearing bone sites. In vitro, the borate BG cement showed a
sustained release of vancomycin into PBS over a longer period
(,36 days) when compared to a commercial CS cement used
clinically (,28 days). When loaded with vancomycin (8 wt%), the
BG cement showed a similar capacity to eradicate MRSA-induced
osteomyelitis compared to CS cement and a better capacity
compared to intravenous injection of vancomycin. The BG
cement also exhibited a good capacity to form new bone in the
defect sites. The BG cement is therefore a promising injectable
carrier for vancomycin in eradicating osteomyelitis and as an
8
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